FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer
Authors:
- 1 March 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 12 (3) , 356-361
Abstract
Learning Objectives: After completing this course, the reader will be able to: Add bevacizumab (Avastin®) to the FOLFOX4 chemotherapy regimen.Evaluate the contribution of bevacizumab and FOLFOX4 to treatment results.Understand FDA criteria for the analysis of response rate and progression-free survival. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.comKeywords
This publication has 4 references indexed in Scilit:
- Lessons from phase III clinical trials on anti-VEGF therapy for cancerNature Clinical Practice Oncology, 2006
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002